##fileformat=VCFv4.1
##fileDate=20200807
##source=strelka
##source_version=2.9.9
##startTime=Fri Aug  7 16:08:23 2020
##cmdline=/mnt/share/opt/strelka-2.9.9.centos6_x86_64/bin//configureStrelkaSomaticWorkflow.py --tumor /mnt/SRV018/projects/diagnostic/SomaticAndTreatment/Sample_DX000000_01/DX000000_01.bam --normal /mnt/SRV018/projects/diagnostic/SomaticAndTreatment/Sample_DX000000_01/DX000000_01.bam --referenceFasta /tmp/local_ngs_data//GRCh37.fa --runDir /tmp/83353.1.default_srv015/megSAP_user_bioinf/vc_strelka2_a5sJrg/strelkaAnalysis --config /mnt/share/opt/strelka-2.9.9.centos6_x86_64/bin//configureStrelkaSomaticWorkflow.py.ini --exome --indelCandidates /mnt/projects/diagnostic/SomaticAndTreatment//Somatic_DX000000_01-DX000000_01//DX000000_01-DX000000_01_manta_var_smallIndels.vcf.gz
##reference=file:///tmp/local_ngs_data/GRCh37.fa
##content=strelka somatic snv calls
##priorSomaticSnvRate=0.0001
##content=strelka somatic indel calls
##priorSomaticIndelRate=1e-06
##CADD_PHRED=PHRED-like scaled CADD score
##CADD_RAW=Raw CADD score
##REVEL=Rare Exome Variant Ensemble Learner
##FATHMM_MKL_C=FATHMM-MKL coding score
##FATHMM_MKL_NC=FATHMM-MKL non-coding score
##MaxEntScan_alt=MaxEntScan alternate sequence score
##MaxEntScan_diff=MaxEntScan score difference
##MaxEntScan_ref=MaxEntScan reference sequence score
##GeneSplicer=GeneSplicer predictions
##ada_score=dbscSNV ADA score
##rf_score=dbscSNV RF score
##VEP="v100" time="2020-08-07 19:36:49" cache="/tmp/local_ngs_data/ensembl-vep-100/homo_sapiens_refseq/100_GRCh37" ensembl-funcgen=100.f0c3948 ensembl-variation=100.b220ff4 ensembl=100.171092c ensembl-io=100.f87ae4f 1000genomes="phase3" COSMIC="90" ClinVar="201912" ESP="20141103" HGMD-PUBLIC="20194" assembly="GRCh37.p13" dbSNP="153" gencode="GENCODE 19" genebuild="2011-04" gnomAD="r2.1" polyphen="2.2.2" refseq="01_2015" regbuild="1.0" sift="sift5.2.2"
##contig=<ID=chr1,length=249250621>
##contig=<ID=chr10,length=135534747>
##contig=<ID=chr11,length=135006516>
##contig=<ID=chr12,length=133851895>
##contig=<ID=chr13,length=115169878>
##contig=<ID=chr14,length=107349540>
##contig=<ID=chr15,length=102531392>
##contig=<ID=chr16,length=90354753>
##contig=<ID=chr17,length=81195210>
##contig=<ID=chr18,length=78077248>
##contig=<ID=chr19,length=59128983>
##contig=<ID=chr2,length=243199373>
##contig=<ID=chr20,length=63025520>
##contig=<ID=chr21,length=48129895>
##contig=<ID=chr22,length=51304566>
##contig=<ID=chr3,length=198022430>
##contig=<ID=chr4,length=191154276>
##contig=<ID=chr5,length=180915260>
##contig=<ID=chr6,length=171115067>
##contig=<ID=chr7,length=159138663>
##contig=<ID=chr8,length=146364022>
##contig=<ID=chr9,length=141213431>
##contig=<ID=chrGL000191.1,length=106433>
##contig=<ID=chrGL000192.1,length=547496>
##contig=<ID=chrGL000193.1,length=189789>
##contig=<ID=chrGL000194.1,length=191469>
##contig=<ID=chrGL000195.1,length=182896>
##contig=<ID=chrGL000196.1,length=38914>
##contig=<ID=chrGL000197.1,length=37175>
##contig=<ID=chrGL000198.1,length=90085>
##contig=<ID=chrGL000199.1,length=169874>
##contig=<ID=chrGL000200.1,length=187035>
##contig=<ID=chrGL000201.1,length=36148>
##contig=<ID=chrGL000202.1,length=40103>
##contig=<ID=chrGL000203.1,length=37498>
##contig=<ID=chrGL000204.1,length=81310>
##contig=<ID=chrGL000205.1,length=174588>
##contig=<ID=chrGL000206.1,length=41001>
##contig=<ID=chrGL000207.1,length=4262>
##contig=<ID=chrGL000208.1,length=92689>
##contig=<ID=chrGL000209.1,length=159169>
##contig=<ID=chrGL000210.1,length=27682>
##contig=<ID=chrGL000211.1,length=166566>
##contig=<ID=chrGL000212.1,length=186858>
##contig=<ID=chrGL000213.1,length=164239>
##contig=<ID=chrGL000214.1,length=137718>
##contig=<ID=chrGL000215.1,length=172545>
##contig=<ID=chrGL000216.1,length=172294>
##contig=<ID=chrGL000217.1,length=172149>
##contig=<ID=chrGL000218.1,length=161147>
##contig=<ID=chrGL000219.1,length=179198>
##contig=<ID=chrGL000220.1,length=161802>
##contig=<ID=chrGL000221.1,length=155397>
##contig=<ID=chrGL000222.1,length=186861>
##contig=<ID=chrGL000223.1,length=180455>
##contig=<ID=chrGL000224.1,length=179693>
##contig=<ID=chrGL000225.1,length=211173>
##contig=<ID=chrGL000226.1,length=15008>
##contig=<ID=chrGL000227.1,length=128374>
##contig=<ID=chrGL000228.1,length=129120>
##contig=<ID=chrGL000229.1,length=19913>
##contig=<ID=chrGL000230.1,length=43691>
##contig=<ID=chrGL000231.1,length=27386>
##contig=<ID=chrGL000232.1,length=40652>
##contig=<ID=chrGL000233.1,length=45941>
##contig=<ID=chrGL000234.1,length=40531>
##contig=<ID=chrGL000235.1,length=34474>
##contig=<ID=chrGL000236.1,length=41934>
##contig=<ID=chrGL000237.1,length=45867>
##contig=<ID=chrGL000238.1,length=39939>
##contig=<ID=chrGL000239.1,length=33824>
##contig=<ID=chrGL000240.1,length=41933>
##contig=<ID=chrGL000241.1,length=42152>
##contig=<ID=chrGL000242.1,length=43523>
##contig=<ID=chrGL000243.1,length=43341>
##contig=<ID=chrGL000244.1,length=39929>
##contig=<ID=chrGL000245.1,length=36651>
##contig=<ID=chrGL000246.1,length=38154>
##contig=<ID=chrGL000247.1,length=36422>
##contig=<ID=chrGL000248.1,length=39786>
##contig=<ID=chrGL000249.1,length=38502>
##contig=<ID=chrhs37d5,length=35477943>
##contig=<ID=chrMT,length=16569>
##contig=<ID=chrNC_007605,length=171823>
##contig=<ID=chrX,length=155270560>
##contig=<ID=chrY,length=59373566>
##INFO=<ID=CLINVAR_DETAILS,Number=.,Type=String,Description="ClinVar disease/significance annotation (from file clinvar_20200506_converted.vcf.gz)">
##INFO=<ID=CLINVAR_ID,Number=.,Type=String,Description="ID column (from file clinvar_20200506_converted.vcf.gz)">
##INFO=<ID=CSQ,Number=.,Type=String,Description="Consequence annotations from Ensembl VEP. Format: Allele|Consequence|IMPACT|SYMBOL|HGNC_ID|Feature|Feature_type|EXON|INTRON|HGVSc|HGVSp|DOMAINS|SIFT|PolyPhen|Existing_variation|AF|gnomAD_AF|gnomAD_AFR_AF|gnomAD_AMR_AF|gnomAD_EAS_AF|gnomAD_NFE_AF|gnomAD_SAS_AF|BIOTYPE|CADD_PHRED|REVEL|FATHMM_MKL_C|FATHMM_MKL_NC|MaxEntScan_ref|MaxEntScan_alt|GeneSplicer|ada_score|rf_score|REPEATMASKER|PHYLOP|OMIM">
##INFO=<ID=CSQ_refseq,Number=.,Type=String,Description="Consequence annotations from Ensembl VEP. Format: Allele|Consequence|IMPACT|SYMBOL|HGNC_ID|Feature|Feature_type|EXON|INTRON|HGVSc|HGVSp|DOMAINS">
##INFO=<ID=DP,Number=1,Type=Integer,Description="Combined depth across samples">
##INFO=<ID=gnomADg_AF,Number=A,Type=Float,Description="Alternate allele frequency in samples (from file gnomAD_genome_r2.1.1.vcf.gz)">
##INFO=<ID=gnomADg_Hemi,Number=A,Type=Integer,Description="Alternate allele count for male samples (from file gnomAD_genome_r2.1.1.vcf.gz)">
##INFO=<ID=gnomADg_Hom,Number=A,Type=Integer,Description="Count of homozygous individuals in samples (from file gnomAD_genome_r2.1.1.vcf.gz)">
##INFO=<ID=HGMD_CLASS,Number=1,Type=String,Description="Mutation Category (from file HGMD_PRO_2020_1_fixed.vcf.gz)", https://portal.biobase-international.com/hgmd/pro/global.php#cats">
##INFO=<ID=HGMD_GENE,Number=1,Type=String,Description="Gene symbol (from file HGMD_PRO_2020_1_fixed.vcf.gz)">
##INFO=<ID=HGMD_ID,Number=.,Type=String,Description="ID column (from file HGMD_PRO_2020_1_fixed.vcf.gz)">
##INFO=<ID=HGMD_MUT,Number=1,Type=String,Description="HGMD mutant allele (from file HGMD_PRO_2020_1_fixed.vcf.gz)">
##INFO=<ID=HGMD_PHEN,Number=1,Type=String,Description="HGMD primary phenotype.  The ' (from file HGMD_PRO_2020_1_fixed.vcf.gz)",' (comma) in primary phenotype descriptions have been replaced with '%2C'.  Instructions to deal with such characters with special meaning are given in Section 1.2 of the VCFv4.3 specfication.">
##INFO=<ID=IC,Number=1,Type=Integer,Description="Number of times RU repeats in the indel allele">
##INFO=<ID=IHP,Number=1,Type=Integer,Description="Largest reference interrupted homopolymer length intersecting with the indel">
##INFO=<ID=MQ,Number=1,Type=Float,Description="RMS Mapping Quality">
##INFO=<ID=MQ0,Number=1,Type=Integer,Description="Total Mapping Quality Zero Reads">
##INFO=<ID=NGSD_CLAS,Number=1,Type=String,Description="Classification from the NGSD. (from file NGSD_germline.vcf.gz)">
##INFO=<ID=NGSD_CLAS_COM,Number=1,Type=String,Description="Classification comment from the NGSD. (from file NGSD_germline.vcf.gz)">
##INFO=<ID=NGSD_COM,Number=1,Type=String,Description="Variant comments from the NGSD. (from file NGSD_germline.vcf.gz)">
##INFO=<ID=NGSD_COUNTS,Number=2,Type=Integer,Description="Homozygous/Heterozygous variant counts in NGSD. (from file NGSD_germline.vcf.gz)">
##INFO=<ID=NGSD_GENE_INFO,Number=.,Type=String,Description="Annotation from /mnt/share/data//dbs/NGSD/NGSD_genes.bed delimited by ':'">
##INFO=<ID=NGSD_GROUP,Number=2,Type=Integer,Description="Homozygous/Heterozygous variant counts in NGSD for neoplasms. (from file NGSD_germline.vcf.gz)">
##INFO=<ID=NGSD_HAF,Number=0,Type=Flag,Description="Indicates a allele frequency above a threshold of 0.05. (from file NGSD_germline.vcf.gz)">
##INFO=<ID=NGSD_SOM_C,Number=1,Type=Integer,Description="Somatic variant count in the NGSD. (from file NGSD_somatic.vcf.gz)">
##INFO=<ID=NGSD_SOM_P,Number=.,Type=String,Description="Project names of project containing this somatic variant in the NGSD. (from file NGSD_somatic.vcf.gz)">
##INFO=<ID=NT,Number=1,Type=String,Description="Genotype of the normal in all data tiers, as used to classify somatic variants. One of {ref,het,hom,conflict}.">
##INFO=<ID=OMIM,Number=.,Type=String,Description="/tmp/local_ngs_data//ensembl-vep-dbs/omim.bed.gz (overlap)">
##INFO=<ID=OVERLAP,Number=0,Type=Flag,Description="Somatic indel possibly overlaps a second indel.">
##INFO=<ID=PHYLOP,Number=.,Type=String,Description="/tmp/local_ngs_data//ensembl-vep-dbs/hg19.100way.phyloP100way.bw (overlap)">
##INFO=<ID=PNOISE,Number=1,Type=Float,Description="Fraction of panel containing non-reference noise at this site">
##INFO=<ID=PNOISE2,Number=1,Type=Float,Description="Fraction of panel containing more than one non-reference noise obs at this site">
##INFO=<ID=QSI,Number=1,Type=Integer,Description="Quality score for any somatic variant, ie. for the ALT haplotype to be present at a significantly different frequency in the tumor and normal">
##INFO=<ID=QSI_NT,Number=1,Type=Integer,Description="Quality score reflecting the joint probability of a somatic variant (indels) and NT">
##INFO=<ID=QSS,Number=1,Type=Integer,Description="Quality score for any somatic snv, ie. for the ALT allele to be present at a significantly different frequency in the tumor and normal">
##INFO=<ID=QSS_NT,Number=1,Type=Integer,Description="Quality score reflecting the joint probability of a somatic variant and NT">
##INFO=<ID=RC,Number=1,Type=Integer,Description="Number of times RU repeats in the reference allele">
##INFO=<ID=ReadPosRankSum,Number=1,Type=Float,Description="Z-score from Wilcoxon rank sum test of Alt Vs. Ref read-position in the tumor">
##INFO=<ID=REPEATMASKER,Number=.,Type=String,Description="/tmp/local_ngs_data//ensembl-vep-dbs/RepeatMasker.bed.gz (overlap)">
##INFO=<ID=RU,Number=1,Type=String,Description="Smallest repeating sequence unit in inserted or deleted sequence">
##INFO=<ID=SGT,Number=1,Type=String,Description="Most likely somatic genotype excluding normal noise states">
##INFO=<ID=SNVSB,Number=1,Type=Float,Description="Somatic SNV site strand bias">
##INFO=<ID=SOMATIC,Number=0,Type=Flag,Description="Somatic mutation">
##INFO=<ID=SomaticEVS,Number=1,Type=Float,Description="Somatic Empirical Variant Score (EVS) expressing the phred-scaled probability of the call being a false positive observation.">
##INFO=<ID=TQSI,Number=1,Type=Integer,Description="Data tier used to compute QSI">
##INFO=<ID=TQSI_NT,Number=1,Type=Integer,Description="Data tier used to compute QSI_NT">
##INFO=<ID=TQSS,Number=1,Type=Integer,Description="Data tier used to compute QSS">
##INFO=<ID=TQSS_NT,Number=1,Type=Integer,Description="Data tier used to compute QSS_NT">
##FILTER=<ID=all-unknown,Description="Allele unknown">
##FILTER=<ID=depth-nor,Description="Sequencing depth in normal is too low (< 20)">
##FILTER=<ID=depth-tum,Description="Sequencing depth in tumor is too low (< 20)">
##FILTER=<ID=freq-nor,Description="Allele frequency in normal > 0.17 * allele frequency in tumor">
##FILTER=<ID=freq-tum,Description="Allele frequency in tumor < 0.05">
##FILTER=<ID=LowDepth,Description="Tumor or normal sample read depth at this locus is below 2">
##FILTER=<ID=LowEVS,Description="Somatic Empirical Variant Score (SomaticEVS) is below threshold">
##FILTER=<ID=lt-3-reads,Description="Less than 3 supporting tumor reads">
##FILTER=<ID=off-target,Description="Variant marked as 'off-target'.">
##FILTER=<ID=special-chromosome,Description="Special chromosome">
##FORMAT=<ID=AU,Number=2,Type=Integer,Description="Number of 'A' alleles used in tiers 1,2">
##FORMAT=<ID=BCN50,Number=1,Type=Float,Description="Fraction of filtered reads within 50 bases of the indel.">
##FORMAT=<ID=CU,Number=2,Type=Integer,Description="Number of 'C' alleles used in tiers 1,2">
##FORMAT=<ID=DP,Number=1,Type=Integer,Description="Read depth for tier1">
##FORMAT=<ID=DP2,Number=1,Type=Integer,Description="Read depth for tier2">
##FORMAT=<ID=DP50,Number=1,Type=Float,Description="Average tier1 read depth within 50 bases">
##FORMAT=<ID=FDP,Number=1,Type=Integer,Description="Number of basecalls filtered from original read depth for tier1">
##FORMAT=<ID=FDP50,Number=1,Type=Float,Description="Average tier1 number of basecalls filtered from original read depth within 50 bases">
##FORMAT=<ID=GU,Number=2,Type=Integer,Description="Number of 'G' alleles used in tiers 1,2">
##FORMAT=<ID=SDP,Number=1,Type=Integer,Description="Number of reads with deletions spanning this site at tier1">
##FORMAT=<ID=SUBDP,Number=1,Type=Integer,Description="Number of reads below tier1 mapping quality threshold aligned across this site">
##FORMAT=<ID=SUBDP50,Number=1,Type=Float,Description="Average number of reads below tier1 mapping quality threshold aligned across sites within 50 bases">
##FORMAT=<ID=TAR,Number=2,Type=Integer,Description="Reads strongly supporting alternate allele for tiers 1,2">
##FORMAT=<ID=TIR,Number=2,Type=Integer,Description="Reads strongly supporting indel allele for tiers 1,2">
##FORMAT=<ID=TOR,Number=2,Type=Integer,Description="Other reads (weak support or insufficient indel breakpoint overlap) for tiers 1,2">
##FORMAT=<ID=TU,Number=2,Type=Integer,Description="Number of 'T' alleles used in tiers 1,2">
##SAMPLE=<ID=DX000000_01,Gender=male,ExternalSampleName=DNA-205275 A1,IsTumor=yes,IsFFPE=yes,DiseaseGroup=n/a,DiseaseStatus=n/a>
##SAMPLE=<ID=DX000000_01,Gender=male,ExternalSampleName=DNA-200281 A1,IsTumor=no,IsFFPE=no,DiseaseGroup=Neoplasms,DiseaseStatus=Affected>
#CHROM	POS	ID	REF	ALT	QUAL	FILTER	INFO	FORMAT	DX000000_01	DX000000_01
chr1	114713909	.	G	T	0	PASS	DP=3108;MQ=59.99;MQ0=0;NT=ref;QSS=320;QSS_NT=3070;ReadPosRankSum=1.02;SGT=GG->GT;SNVSB=0.00;SOMATIC;SomaticEVS=12.57;TQSS=2;TQSS_NT=1;CSQ=T|downstream_gene_variant|MODIFIER|CSDE1|29905|ENST00000261443|Transcript||||||||rs121913254&COSV54736310&COSV54743343&COSV54752117||0|0|0|0|0|0|protein_coding|26.3||0.99393|0.99357|||||||9.52400016784668|164790_[GENE%3DNRAS_PHENOS%3DEpidermal_nevus&somatic&162900/Melanocytic_nevus_syndrome&congenital&somatic&137550/Schimmelpenning-Feuerstein-Mims_syndrome&somatic_mosaic&163200/Colorectal_cancer&somatic&114500/RAS-associated_autoimmune_lymphoproliferative_syndrome_type_IV&somatic&614470/Thyroid_carcinoma&follicular&somatic&188470/Neurocutaneous_melanosis&somatic&249400/Noonan_syndrome_6&613224&Autosomal_dominant],T|downstream_gene_variant|MODIFIER|CSDE1|29905|ENST00000339438|Transcript||||||||rs121913254&COSV54736310&COSV54743343&COSV54752117||0|0|0|0|0|0|protein_coding|26.3||0.99393|0.99357|||||||9.52400016784668|164790_[GENE%3DNRAS_PHENOS%3DEpidermal_nevus&somatic&162900/Melanocytic_nevus_syndrome&congenital&somatic&137550/Schimmelpenning-Feuerstein-Mims_syndrome&somatic_mosaic&163200/Colorectal_cancer&somatic&114500/RAS-associated_autoimmune_lymphoproliferative_syndrome_type_IV&somatic&614470/Thyroid_carcinoma&follicular&somatic&188470/Neurocutaneous_melanosis&somatic&249400/Noonan_syndrome_6&613224&Autosomal_dominant],T|downstream_gene_variant|MODIFIER|CSDE1|29905|ENST00000358528|Transcript||||||||rs121913254&COSV54736310&COSV54743343&COSV54752117||0|0|0|0|0|0|protein_coding|26.3||0.99393|0.99357|||||||9.52400016784668|164790_[GENE%3DNRAS_PHENOS%3DEpidermal_nevus&somatic&162900/Melanocytic_nevus_syndrome&congenital&somatic&137550/Schimmelpenning-Feuerstein-Mims_syndrome&somatic_mosaic&163200/Colorectal_cancer&somatic&114500/RAS-associated_autoimmune_lymphoproliferative_syndrome_type_IV&somatic&614470/Thyroid_carcinoma&follicular&somatic&188470/Neurocutaneous_melanosis&somatic&249400/Noonan_syndrome_6&613224&Autosomal_dominant],T|downstream_gene_variant|MODIFIER|CSDE1|29905|ENST00000369530|Transcript||||||||rs121913254&COSV54736310&COSV54743343&COSV54752117||0|0|0|0|0|0|protein_coding|26.3||0.99393|0.99357|||||||9.52400016784668|164790_[GENE%3DNRAS_PHENOS%3DEpidermal_nevus&somatic&162900/Melanocytic_nevus_syndrome&congenital&somatic&137550/Schimmelpenning-Feuerstein-Mims_syndrome&somatic_mosaic&163200/Colorectal_cancer&somatic&114500/RAS-associated_autoimmune_lymphoproliferative_syndrome_type_IV&somatic&614470/Thyroid_carcinoma&follicular&somatic&188470/Neurocutaneous_melanosis&somatic&249400/Noonan_syndrome_6&613224&Autosomal_dominant],T|missense_variant|MODERATE|NRAS|7989|ENST00000369535|Transcript|3/7||ENST00000369535.4:c.181C>A|ENSP00000358548.4:p.Gln61Lys|PROSITE_profiles:PS51421&hmmpanther:PTHR24070:SF189&hmmpanther:PTHR24070&Gene3D:3.40.50.300&TIGRFAM_domain:TIGR00231&Pfam_domain:PF00071&SMART_domains:SM00173&SMART_domains:SM00175&SMART_domains:SM00174&Superfamily_domains:SSF52540&Prints_domain:PR00449|deleterious(0.01)|possibly_damaging(0.709)|rs121913254&COSV54736310&COSV54743343&COSV54752117||0|0|0|0|0|0|protein_coding|26.3|0.841|0.99393|0.99357|||||||9.52400016784668|164790_[GENE%3DNRAS_PHENOS%3DEpidermal_nevus&somatic&162900/Melanocytic_nevus_syndrome&congenital&somatic&137550/Schimmelpenning-Feuerstein-Mims_syndrome&somatic_mosaic&163200/Colorectal_cancer&somatic&114500/RAS-associated_autoimmune_lymphoproliferative_syndrome_type_IV&somatic&614470/Thyroid_carcinoma&follicular&somatic&188470/Neurocutaneous_melanosis&somatic&249400/Noonan_syndrome_6&613224&Autosomal_dominant],T|downstream_gene_variant|MODIFIER|CSDE1|29905|ENST00000438362|Transcript||||||||rs121913254&COSV54736310&COSV54743343&COSV54752117||0|0|0|0|0|0|protein_coding|26.3||0.99393|0.99357|||||||9.52400016784668|164790_[GENE%3DNRAS_PHENOS%3DEpidermal_nevus&somatic&162900/Melanocytic_nevus_syndrome&congenital&somatic&137550/Schimmelpenning-Feuerstein-Mims_syndrome&somatic_mosaic&163200/Colorectal_cancer&somatic&114500/RAS-associated_autoimmune_lymphoproliferative_syndrome_type_IV&somatic&614470/Thyroid_carcinoma&follicular&somatic&188470/Neurocutaneous_melanosis&somatic&249400/Noonan_syndrome_6&613224&Autosomal_dominant],T|downstream_gene_variant|MODIFIER|CSDE1|29905|ENST00000530886|Transcript||||||||rs121913254&COSV54736310&COSV54743343&COSV54752117||0|0|0|0|0|0|protein_coding|26.3||0.99393|0.99357|||||||9.52400016784668|164790_[GENE%3DNRAS_PHENOS%3DEpidermal_nevus&somatic&162900/Melanocytic_nevus_syndrome&congenital&somatic&137550/Schimmelpenning-Feuerstein-Mims_syndrome&somatic_mosaic&163200/Colorectal_cancer&somatic&114500/RAS-associated_autoimmune_lymphoproliferative_syndrome_type_IV&somatic&614470/Thyroid_carcinoma&follicular&somatic&188470/Neurocutaneous_melanosis&somatic&249400/Noonan_syndrome_6&613224&Autosomal_dominant],T|downstream_gene_variant|MODIFIER|CSDE1|29905|ENST00000534699|Transcript||||||||rs121913254&COSV54736310&COSV54743343&COSV54752117||0|0|0|0|0|0|protein_coding|26.3||0.99393|0.99357|||||||9.52400016784668|164790_[GENE%3DNRAS_PHENOS%3DEpidermal_nevus&somatic&162900/Melanocytic_nevus_syndrome&congenital&somatic&137550/Schimmelpenning-Feuerstein-Mims_syndrome&somatic_mosaic&163200/Colorectal_cancer&somatic&114500/RAS-associated_autoimmune_lymphoproliferative_syndrome_type_IV&somatic&614470/Thyroid_carcinoma&follicular&somatic&188470/Neurocutaneous_melanosis&somatic&249400/Noonan_syndrome_6&613224&Autosomal_dominant];CSQ_refseq=T|downstream_gene_variant|MODIFIER|CSDE1||NM_001007553.3|Transcript|||||,T|downstream_gene_variant|MODIFIER|CSDE1||NM_001130523.3|Transcript|||||,T|downstream_gene_variant|MODIFIER|CSDE1||NM_001242891.1|Transcript|||||,T|downstream_gene_variant|MODIFIER|CSDE1||NM_001242892.2|Transcript|||||,T|downstream_gene_variant|MODIFIER|CSDE1||NM_001242893.2|Transcript|||||,T|missense_variant|MODERATE|NRAS||NM_002524.5|Transcript|3/7||NM_002524.5:c.181C>A|NP_002515.1:p.Gln61Lys|,T|downstream_gene_variant|MODIFIER|CSDE1||NM_007158.6|Transcript|||||;CLINVAR_ID=73058;CLINVAR_DETAILS=uncertain_significance%20DISEASE%3DRAS_Inhibitor_response%2CVascular_Tumors_Including_Pyogenic_Granuloma%2CHepatocellular_carcinoma%2CNeuroblastoma%2CAcute_myeloid_leukemia%2CChronic_lymphocytic_leukemia%2CRenal_cell_carcinoma%2C_papillary%2C_1%2CLarge_congenital_melanocytic_nevus%2CTransitional_cell_carcinoma_of_the_bladder%2CAdrenocortical_carcinoma%2CMultiple_myeloma%2CCutaneous_melanoma%2CLung_adenocarcinoma%2CNon-small_cell_lung_cancer%2CNeoplasm_of_brain%2CNeoplasm_of_the_large_intestine%2CMalignant_melanoma_of_skin%2CGlioblastoma%2CNasopharyngeal_Neoplasms%2CMalignant_neoplasm_of_body_of_uterus%2CAdenocarcinoma_of_stomach%2COvarian_Serous_Cystadenocarcinoma%2CNeurocutaneous_melanocytosis%2CRasopathy;NGSD_COUNTS=0,1;NGSD_CLAS_COM="[import%20GPD]%20Christopher%20Schroeder%202013-09-09%2011:18:14%0A-type:%20lit%20/%20general%0A-link:%20http://jco.ascopubs.org/content/31/26/3173?cmpid%3Djco_etoc_10September2013%0A-doi:%2010.1200/JCO.2013.50.3144%0A-drugs:%20imatinib%0AAnother%20Option%20in%20Our%20KIT%20of%20Effective%20Therapies%20for%20Advanced%20Melanoma%0A%3D>%20Of%2024%20evaluable%20patients%2C%20seven%20achieved%20a%20partial%20response%20(PR)%20to%20therapy%2C%20with%20five%20patients'%20responses%20confirmed%20on%20subsequent%20imaging%20studies%2C%20for%20an%20overall%20confirmed%20response%20rate%20(RR)%20of%2021%25.%20This%20clinical%20activity%20is%20similar%20to%20that%20observed%20in%20two%20other%20trials%20of%20imatinib%20in%20patients%20with%20melanoma%20molecularly%20selected%20for%20the%20presence%20of%20KIT%20alterations.%20Our%20group3%20screened%20295%20patients%20for%20KIT%20mutations%20or%20amplification%2C%20identified%2051%20patients%20with%20such%20alterations%2C%20treated%2025%20evaluable%20patients%2C%20and%20observed%20a%20confirmed%20RR%20of%2016%25%2C%20with%20responses%20durable%20for%20longer%20than%201%20year.%20Guo%20et%20al4%20screened%20501%20patients%20for%20KIT%20mutations%20or%20amplification%2C%20treated%2043%20patients%20with%20imatinib%2C%20and%20observed%20an%20RR%20of%2023.3%25.%20The%20significance%20of%20the%20responses%20observed%20on%20these%20three%20trials%20is%20most%20evident%20when%20placed%20in%20the%20context%20of%20three%20prior%20negative%20phase%20II%20trials%20of%20imatinib%20in%20molecularly%20unselected%20melanoma%20patients%20initiated%20before%20the%20identification%20of%20KIT%20mutations%20in%20this%20disease%2C%20in%20which%20only%20one%20radiographic%20response%20was%20observed%20in%2062%20patients%20treated%20across%20the%20three%20trials.5–7%0A%0A%3D>%20Although%20approximately%2070%25%20of%20KIT%20mutations%20identified%20in%20melanoma%20affect%20the%20juxtamembrane%20domain%20(exon%2011%2C%20most%20commonly%20L576P)%20and%20the%20proximal%20kinase%20domain%20(exon%2013%2C%20most%20commonly%20K642E)%2C%20others%20have%20been%20identified%20that%20likely%20represent%20passenger%20mutations%20of%20no%20biologic%20significance.%20%0A%3D>%20NRAS%20Q61K%20mutation%20plus%20a%20previously%20detected%20W557G%20KIT%20mutation%20was%20also%20identified%20in%20a%20secondarily%20resistant%20tumor%20after%20a%207-month%20course%20of%20sunitinib%2C%20suggesting%20that%20NRAS%20mutations%20may%20also%20be%20a%20mechanism%20of%20secondary%20resistance%20to%20KIT%20inhibition.12%2C14%0A[3]%20ahwittd1%2008.04.2020%0A[5]%20ahwittd1%2008.04.2020%0A[n/a]%20ahwittd1%2008.04.2020";NGSD_SOM_C=56;NGSD_SOM_P=ALM_Schleimhautmelanom,Leuk,Novartis,OvCa,Ringversuch_EMQN,Roecken_CheckpointInhibitor,SomaticAndTreatment,TEST_SomaticAndTreatment,eMed-HCC;NGSD_GENE_INFO=NRAS%20(inh%3DAD%20oe_syn%3D1.00%20oe_mis%3D0.53%20oe_lof%3D0.19):CSDE1%20(inh%3Dn/a%20oe_syn%3D0.96%20oe_mis%3D0.55%20oe_lof%3D0.05)	AU:BCN50:CU:DP:DP2:DP50:FDP:FDP50:GU:SDP:SUBDP:SUBDP50:TAR:TIR:TOR:TU	0,0:.:0,1:1005:.:.:12:.:992,1028:0:0:.:.:.:.:1,2	0,0:.:0,0:2028:.:.:4:.:1861,1906:0:0:.:.:.:.:163,171
chr5	1295135	.	G	A	0	PASS	DP=256;MQ=59.87;MQ0=0;NT=ref;QSS=191;QSS_NT=3070;ReadPosRankSum=1.25;SGT=GG->AG;SNVSB=0.00;SOMATIC;SomaticEVS=18.46;TQSS=1;TQSS_NT=1;CSQ=A|upstream_gene_variant|MODIFIER|TERT|11730|ENST00000296820|Transcript||||||||rs1561215364||||||||protein_coding|6.889||0.00304|0.95933|||||||-1.24600005149841|,A|upstream_gene_variant|MODIFIER|TERT|11730|ENST00000310581|Transcript||||||||rs1561215364||||||||protein_coding|6.889||0.00304|0.95933|||||||-1.24600005149841|,A|upstream_gene_variant|MODIFIER|TERT|11730|ENST00000334602|Transcript||||||||rs1561215364||||||||protein_coding|6.889||0.00304|0.95933|||||||-1.24600005149841|,A|upstream_gene_variant|MODIFIER|TERT|11730|ENST00000508104|Transcript||||||||rs1561215364||||||||protein_coding|6.889||0.00304|0.95933|||||||-1.24600005149841|,A|regulatory_region_variant|MODIFIER|||ENSR00001317615|RegulatoryFeature||||||||rs1561215364||||||||promoter|6.889||0.00304|0.95933|||||||-1.24600005149841|;CSQ_refseq=A|upstream_gene_variant|MODIFIER|TERT||NM_001193376.2|Transcript|||||,A|upstream_gene_variant|MODIFIER|TERT||NM_198253.3|Transcript|||||,A|upstream_gene_variant|MODIFIER|TERT||NR_149162.2|Transcript|||||,A|upstream_gene_variant|MODIFIER|TERT||NR_149163.2|Transcript|||||;NGSD_COUNTS=0,2;NGSD_COM="c.-146C>T";NGSD_SOM_C=77;NGSD_SOM_P=Novartis,Roecken_CheckpointInhibitor,SomaticAndTreatment;NGSD_GENE_INFO=TERT%20(inh%3DAD%20oe_syn%3D0.98%20oe_mis%3D0.49%20oe_lof%3D0.16)	AU:BCN50:CU:DP:DP2:DP50:FDP:FDP50:GU:SDP:SUBDP:SUBDP50:TAR:TIR:TOR:TU	0,0:.:0,0:135:.:.:15:.:119,133:0:0:.:.:.:.:1,3	40,44:.:0,0:120:.:.:9:.:71,75:0:0:.:.:.:.:0,0
chr7	140753336	.	A	T	0	PASS	DP=3703;MQ=59.98;MQ0=0;NT=ref;QSS=2527;QSS_NT=3070;ReadPosRankSum=-0.47;SGT=AA->AT;SNVSB=0.00;SOMATIC;SomaticEVS=17.62;TQSS=1;TQSS_NT=1;CSQ=T|missense_variant|MODERATE|BRAF|1097|ENST00000288602|Transcript|15/18||ENST00000288602.6:c.1799T>A|ENSP00000288602.6:p.Val600Glu|PROSITE_profiles:PS50011&hmmpanther:PTHR23257:SF360&hmmpanther:PTHR23257&Pfam_domain:PF07714&Gene3D:1.10.510.10&SMART_domains:SM00220&Superfamily_domains:SSF56112|deleterious(0)|probably_damaging(0.963)|rs113488022&CM112509&COSV56056643&COSV56065204&COSV56080151||3.98e-06|0|0|0|0|3.267e-05|protein_coding|28.8|0.931|0.98542|0.99470|||||||9.20100021362305|164757_[GENE%3DBRAF_PHENOS%3DNonsmall_cell_lung_cancer&somatic/Melanoma&malignant&somatic/Noonan_syndrome_7&613706&Autosomal_dominant/Cardiofaciocutaneous_syndrome&115150&Autosomal_dominant/Colorectal_cancer&somatic/Adenocarcinoma_of_lung&somatic&211980/LEOPARD_syndrome_3&613707&Autosomal_dominant];CSQ_refseq=T|missense_variant|MODERATE|BRAF||NM_001354609.2|Transcript|15/19||NM_001354609.2:c.1799T>A|NP_001341538.1:p.Val600Glu|,T|missense_variant|MODERATE|BRAF||NM_004333.6|Transcript|15/18||NM_004333.6:c.1799T>A|NP_004324.2:p.Val600Glu|,T|non_coding_transcript_exon_variant|MODIFIER|BRAF||NR_148928.2|Transcript|15/18||NR_148928.2:n.2898T>A||;CLINVAR_ID=13961;CLINVAR_DETAILS=pathogenic%2C_drug_response%2C_other%20DISEASE%3DCystic_epithelial_invagination_containing_papillae_lined_by_columnar_epithelium%2CTrametinib-Dabrafenib_Response%2CVemurafenib-Cobimetinib_Response%2CCerebral_arteriovenous_malformation%2CNeoplasm%2CPapillary_thyroid_carcinoma%2CMultiple_myeloma%2CBrainstem_glioma%2CCutaneous_melanoma%2CLung_adenocarcinoma%2CNon-small_cell_lung_cancer%2CNeoplasm_of_brain%2CColonic_neoplasm%2CGastrointestinal_stromal_tumor%2CNeoplasm_of_the_large_intestine%2CSquamous_cell_carcinoma_of_the_head_and_neck%2CPapillary_renal_cell_carcinoma%2C_sporadic%2CMalignant_melanoma_of_skin%2CGlioblastoma%2COvarian_Neoplasms%2CCarcinoma_of_colon%2CLung_cancer%2CGerm_cell_tumor%2C_nonseminomatous%2CCardio-facio-cutaneous_syndrome%2CColorectal_cancer%2CAstrocytoma%2C_low-grade%2C_somatic%2Cnot_provided;NGSD_COUNTS=3,4;NGSD_GROUP=1,0;NGSD_CLAS_COM="[import%20GPD]%20Christopher%20Schroeder%202013-05-07%2009:14:08%0A-type:%20lit%20/%20general%0A-link:%20http://www.ncbi.nlm.nih.gov/pubmed/21663470?dopt%3DAbstract&holding%3Dnpg%0A-doi:%2010.1056/NEJMoa1014209%0ABRAF%20mutations%20in%20hairy-cell%20leukemia.%0A%0A[import%20GPD]%20Christopher%20Schroeder%202013-05-07%2009:14:45%0A-type:%20lit%20/%20general%0A-link:%20http://www.ncbi.nlm.nih.gov/pubmed/22210875?dopt%3DAbstract&holding%3Dnpg%0A-doi:%2010.1182/blood-2011-09-379339%0ABoth%20variant%20and%20IGHV4-34-expressing%20hairy%20cell%20leukemia%20lack%20the%20BRAF%20V600E%20mutation.%0A%0A[import%20GPD]%20Christopher%20Schroeder%202013-05-02%2017:26:11%0A-type:%20lit%20/%20druggable%0A-link:%20http://www.nejm.org/doi/full/10.1056/NEJMc1215697?query%3DTOC%0A-drugs:%20vemurafenib%0ABRAF%20V600E%20Inhibition%20in%20Anaplastic%20Thyroid%20Cancer%0A%0A[import%20GPD]%20Christopher%20Schroeder%202013-05-07%2018:21:28%0A-type:%20lit%20/%20general%0A-link:%20http://www.ncbi.nlm.nih.gov/pubmed/22395615?dopt%3DAbstract&holding%3Dnpg%0A-doi:%2010.1038/ncomms1727%0AMelanoma%20whole-exome%20sequencing%20identifies%20(V600E)B-RAF%20amplification-mediated%20acquired%20B-RAF%20inhibitor%20resistance.%0A%0A[import%20GPD]%20Christopher%20Schroeder%202013-05-15%2011:43:10%0A-type:%20lit%20/%20preclinical%20study%0A-link:%20http://www.nature.com/nature/journal/v483/n7387/full/nature10868.html%0A-doi:%2010.1038/nature10868%0A-drugs:%20vemurafenib%2C%20cetuximab%2C%20gefitinib%2C%20panitumumab%0AUnresponsiveness%20of%20colon%20cancer%20to%20BRAF(V600E)%20inhibition%20through%20feedback%20activation%20of%20EGFR.%20%0A%3D>%20Our%20data%20suggest%20that%20BRAF(V600E)%20mutant%20colon%20cancers%20(approximately%208–10%25%20of%20all%20colon%20cancers2%2C%203%2C%205)%2C%20for%20which%20there%20are%20currently%20no%20targeted%20treatment%20options%20available%2C%20might%20benefit%20from%20combination%20therapy%20consisting%20of%20BRAF%20and%20EGFR%20inhibitors.%0A%0A[import%20GPD]%20Christopher%20Schroeder%202013-05-03%2017:12:18%0A-type:%20lit%20/%20druggable%0A-link:%20http://www.nejm.org/doi/full/10.1056/NEJMoa1103782%0A-drugs:%20vemurafenib%0AImproved%20Survival%20with%20Vemurafenib%20in%20Melanoma%20with%20BRAF%20V600E%20Mutation%0A%0A[import%20GPD]%20Christopher%20Schroeder%202013-05-28%2015:50:19%0A-type:%20lit%20/%20general%0A-link:%20http://www.ncbi.nlm.nih.gov/pubmed/20818844%0A-doi:%2010.1056/NEJMoa1002011%0A-drugs:%20vemurafenib%0AInhibition%20of%20mutated%2C%20activated%20BRAF%20in%20metastatic%20melanoma.%0A%3D>%20Treatment%20of%20metastatic%20melanoma%20with%20PLX4032%20in%20patients%20with%20tumors%20that%20carry%20the%20V600E%20BRAF%20mutation%20resulted%20in%20complete%20or%20partial%20tumor%20regression%20in%20the%20majority%20of%20patients.%0A%0A[import%20GPD]%20Christopher%20Schroeder%202013-06-05%2015:32:18%0A-type:%20lit%20/%20druggable%0A-link:%20http://jco.ascopubs.org/content/early/2013/06/03/JCO.2012.45.7739?papetoc%0A-doi:%2010.1200/JCO.2012.45.7739%0A-drugs:%20vemurafenib%0ARapid%20Response%20to%20Vemurafenib%20in%20a%20Heavily%20Pretreated%20Patient%20With%20Hairy%20Cell%20Leukemia%20and%20a%20BRAF%20Mutation%0A%0A[import%20GPD]%20Christopher%20Schroeder%202013-09-04%2010:29:28%0A-type:%20lit%20/%20preclinical%20study%0A-link:%20http://www.ncbi.nlm.nih.gov/pubmed/18676837%0A-doi:%2010.1158/0008-5472.CAN-08-1430%0A-drugs:%20selumetinib%2C%20Trametinib%0ATumors%20harboring%20BRAF%20V600E%20mutations%20lack%20this%20negative%20feedback%20loop%20and%20are%20sensitive%20to%20MEK%20inhibitors.%0A%0A[import%20GPD]%20Christopher%20Schroeder%202013-12-22%2015:16:45%0A-type:%20lit%20/%20clinical%20trial%0A-link:%20http://jco.ascopubs.org/content/31/35/e448?cmpid%3Djco_etoc_10December2013%0A-doi:%2010.1200/JCO.2013.50.4118%0A-drugs:%20dabrafenib%2C%20Trametinib%0ABRAF%20Inhibitor–Driven%20Tumor%20Proliferation%20in%20a%20KRAS-Mutated%20Colon%20Carcinoma%20Is%20Not%20Overcome%20by%20MEK1/2%20Inhibition%0A%3D>%20First%2C%20caution%20must%20be%20exercised%20when%20using%20BRAFis%20in%20patients%20or%20populations%20that%20might%20harbor%20RAS-mutated%20cells%2C%20be%20they%20in%20skin%2C%20bowel%2C%20or%20other%20sites.%0A%0A[import%20GPD]%20Christopher%20Schroeder%202013-06-05%2015:27:37%0A-type:%20case%20report%0A-link:%20http://jco.ascopubs.org/content/early/2013/06/03/JCO.2012.47.6143?papetoc%0A-doi:%2010.1200/JCO.2012.47.6143%0A-drugs:%20vemurafenib%2C%20radiation%0ADramatic%20Response%20Induced%20by%0AVemurafenib%20in%20a%20BRAF%20V600E-Mutated%0ALung%20Adenocarcinoma.%20Radiosensitizing%20effect%20of%20vemurafenib%20("should%20probably%20not%20be%20combined%20with%20radiation").";NGSD_SOM_C=138;NGSD_SOM_P=ALM_Schleimhautmelanom,ARO-16,E19D025_Schulte_Ulm,Novartis,PATHO_Somatic,Roecken_CheckpointInhibitor,SomaticAndTreatment,TEST_cfDNA_ThruPLEX_Tag-seq;NGSD_GENE_INFO=BRAF%20(inh%3DAR+AD%20oe_syn%3D1.02%20oe_mis%3D0.49%20oe_lof%3D0.10)	AU:BCN50:CU:DP:DP2:DP50:FDP:FDP50:GU:SDP:SUBDP:SUBDP50:TAR:TIR:TOR:TU	1049,1070:.:1,2:1062:.:.:12:.:0,0:0:0:.:.:.:.:0,2	1308,1315:.:0,0:2619:.:.:8:.:0,0:0:0:.:.:.:.:1303,1312
chr9	5072490	.	A	C	0	PASS	DP=471;MQ=60.00;MQ0=0;NT=ref;QSS=520;QSS_NT=3070;ReadPosRankSum=0.09;SGT=AA->AC;SNVSB=0.00;SOMATIC;SomaticEVS=19.73;TQSS=1;TQSS_NT=1;CSQ=C|splice_acceptor_variant|HIGH|JAK2|6192|ENST00000381652|Transcript||12/24|ENST00000381652.3:c.1642-2A>C|||||||||||||protein_coding|35||0.98787|0.99320|9.555|1.513|loss/acceptor/5072490-5072491/Medium/7.779510|0.999988247793601|0.93||8.94699954986572|147796_[GENE%3DJAK2_PHENOS%3DMyelofibrosis&somatic&254450/Thrombocythemia_3&614521&Somatic_mutation&Autosomal_dominant/Polycythemia_vera&somatic&263300/Budd-Chiari_syndrome&somatic&600880/Leukemia&acute_myeloid&somatic&601626/Erythrocytosis&somatic&133100],C|splice_acceptor_variant|HIGH|JAK2|6192|ENST00000539801|Transcript||11/23|ENST00000539801.1:c.1642-2A>C|||||||||||||protein_coding|35||0.98787|0.99320|9.555|1.513|loss/acceptor/5072490-5072491/Medium/7.779510|0.999988247793601|0.93||8.94699954986572|147796_[GENE%3DJAK2_PHENOS%3DMyelofibrosis&somatic&254450/Thrombocythemia_3&614521&Somatic_mutation&Autosomal_dominant/Polycythemia_vera&somatic&263300/Budd-Chiari_syndrome&somatic&600880/Leukemia&acute_myeloid&somatic&601626/Erythrocytosis&somatic&133100],C|splice_acceptor_variant|HIGH|JAK2|6192|ENST00000544510|Transcript||9/21|ENST00000544510.1:c.1195-2A>C|||||||||||||protein_coding|35||0.98787|0.99320|9.555|1.513|loss/acceptor/5072490-5072491/Medium/7.779510|0.999988247793601|0.93||8.94699954986572|147796_[GENE%3DJAK2_PHENOS%3DMyelofibrosis&somatic&254450/Thrombocythemia_3&614521&Somatic_mutation&Autosomal_dominant/Polycythemia_vera&somatic&263300/Budd-Chiari_syndrome&somatic&600880/Leukemia&acute_myeloid&somatic&601626/Erythrocytosis&somatic&133100],C|downstream_gene_variant|MODIFIER|AL161450.1||ENST00000601793|Transcript||||||||||||||||protein_coding|35||0.98787|0.99320||||0.999988247793601|0.93||8.94699954986572|147796_[GENE%3DJAK2_PHENOS%3DMyelofibrosis&somatic&254450/Thrombocythemia_3&614521&Somatic_mutation&Autosomal_dominant/Polycythemia_vera&somatic&263300/Budd-Chiari_syndrome&somatic&600880/Leukemia&acute_myeloid&somatic&601626/Erythrocytosis&somatic&133100];CSQ_refseq=C|splice_acceptor_variant|HIGH|JAK2||NM_001322194.1|Transcript||12/24|NM_001322194.1:c.1642-2A>C||,C|splice_acceptor_variant|HIGH|JAK2||NM_001322195.1|Transcript||11/23|NM_001322195.1:c.1642-2A>C||,C|splice_acceptor_variant|HIGH|JAK2||NM_001322196.1|Transcript||11/23|NM_001322196.1:c.1642-2A>C||,C|splice_acceptor_variant|HIGH|JAK2||NM_001322198.1|Transcript||12/24|NM_001322198.1:c.427-2A>C||,C|splice_acceptor_variant|HIGH|JAK2||NM_001322199.1|Transcript||12/24|NM_001322199.1:c.427-2A>C||,C|splice_acceptor_variant|HIGH|JAK2||NM_001322204.1|Transcript||9/21|NM_001322204.1:c.1195-2A>C||,C|splice_acceptor_variant|HIGH|JAK2||NM_004972.3|Transcript||12/24|NM_004972.3:c.1642-2A>C||;NGSD_GENE_INFO=JAK2%20(inh%3DAD%20oe_syn%3D1.11%20oe_mis%3D0.90%20oe_lof%3D0.21)	AU:BCN50:CU:DP:DP2:DP50:FDP:FDP50:GU:SDP:SUBDP:SUBDP50:TAR:TIR:TOR:TU	218,225:.:0,0:224:.:.:6:.:0,0:0:0:.:.:.:.:0,0	111,111:.:131,135:242:.:.:0:.:0,0:0:0:.:.:.:.:0,0
chr9	21971018	.	G	A	0	PASS	DP=2471;MQ=59.85;MQ0=0;NT=ref;QSS=2508;QSS_NT=3070;ReadPosRankSum=-0.49;SGT=GG->AG;SNVSB=0.00;SOMATIC;SomaticEVS=17.62;TQSS=1;TQSS_NT=1;CSQ=A|missense_variant|MODERATE|CDKN2A|1787|ENST00000304494|Transcript|2/3||ENST00000304494.5:c.341C>T|ENSP00000307101.5:p.Pro114Leu|Gene3D:1.25.40.20&Pfam_domain:PF12796&PROSITE_profiles:PS50297&hmmpanther:PTHR24144&hmmpanther:PTHR24144:SF30&Superfamily_domains:SSF48403|deleterious(0)|probably_damaging(0.999)|rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|protein_coding|32|0.872|0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant],A|synonymous_variant|LOW|CDKN2A|1787|ENST00000361570|Transcript|2/3||ENST00000361570.3:c.507C>T|ENSP00000355153.3:p.Ala169%3D||||rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|protein_coding|32||0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant],A|intron_variant&NMD_transcript_variant|MODIFIER|RP11-145E5.5||ENST00000404796|Transcript||4/5|ENST00000404796.2:c.348-58415G>A|||||rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|nonsense_mediated_decay|32||0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant],A|downstream_gene_variant|MODIFIER|C9orf53|23831|ENST00000441769|Transcript||||||||rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|protein_coding|32||0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant],A|missense_variant|MODERATE|CDKN2A|1787|ENST00000446177|Transcript|2/3||ENST00000446177.1:c.341C>T|ENSP00000394932.1:p.Pro114Leu|PROSITE_profiles:PS50297&hmmpanther:PTHR24144:SF30&hmmpanther:PTHR24144&Pfam_domain:PF12796&Gene3D:1.25.40.20&Superfamily_domains:SSF48403|deleterious(0)|probably_damaging(1)|rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|protein_coding|32|0.872|0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant],A|missense_variant|MODERATE|CDKN2A|1787|ENST00000479692|Transcript|2/3||ENST00000479692.2:c.188C>T|ENSP00000466887.1:p.Pro63Leu|Gene3D:1.25.40.20&Pfam_domain:PF12796&PROSITE_profiles:PS50297&hmmpanther:PTHR24144&hmmpanther:PTHR24144:SF30&Superfamily_domains:SSF48403|deleterious(0)|probably_damaging(1)|rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|protein_coding|32|0.872|0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant],A|missense_variant|MODERATE|CDKN2A|1787|ENST00000494262|Transcript|3/4||ENST00000494262.1:c.188C>T|ENSP00000464952.1:p.Pro63Leu|Gene3D:1.25.40.20&Pfam_domain:PF12796&PROSITE_profiles:PS50297&hmmpanther:PTHR24144&hmmpanther:PTHR24144:SF30&Superfamily_domains:SSF48403|deleterious(0)|probably_damaging(0.999)|rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|protein_coding|32|0.872|0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant],A|missense_variant|MODERATE|CDKN2A|1787|ENST00000497750|Transcript|2/2||ENST00000497750.1:c.188C>T|ENSP00000468510.1:p.Pro63Leu|Gene3D:1.25.40.20&Pfam_domain:PF12796&PROSITE_profiles:PS50297&hmmpanther:PTHR24144&hmmpanther:PTHR24144:SF30&Superfamily_domains:SSF48403|deleterious(0)|probably_damaging(1)|rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|protein_coding|32|0.872|0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant],A|missense_variant|MODERATE|CDKN2A|1787|ENST00000498124|Transcript|2/4||ENST00000498124.1:c.341C>T|ENSP00000418915.1:p.Pro114Leu|PROSITE_profiles:PS50297&hmmpanther:PTHR24144:SF30&hmmpanther:PTHR24144&Gene3D:1.25.40.20&Pfam_domain:PF12796&Superfamily_domains:SSF48403|deleterious(0)|probably_damaging(1)|rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|protein_coding|32|0.872|0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant],A|missense_variant|MODERATE|CDKN2A|1787|ENST00000498628|Transcript|2/3||ENST00000498628.2:c.188C>T|ENSP00000467857.1:p.Pro63Leu|Gene3D:1.25.40.20&Pfam_domain:PF12796&PROSITE_profiles:PS50297&hmmpanther:PTHR24144&hmmpanther:PTHR24144:SF30&Superfamily_domains:SSF48403|deleterious(0)|probably_damaging(0.999)|rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|protein_coding|32|0.872|0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant],A|synonymous_variant|LOW|CDKN2A|1787|ENST00000530628|Transcript|2/3||ENST00000530628.2:c.384C>T|ENSP00000432664.2:p.Ala128%3D||||rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|protein_coding|32||0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant],A|missense_variant|MODERATE|CDKN2A|1787|ENST00000578845|Transcript|1/2||ENST00000578845.2:c.188C>T|ENSP00000467390.1:p.Pro63Leu|Gene3D:1.25.40.20&Pfam_domain:PF12796&PROSITE_profiles:PS50297&hmmpanther:PTHR24144&hmmpanther:PTHR24144:SF30&Superfamily_domains:SSF48403|deleterious(0)|probably_damaging(0.999)|rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|protein_coding|32|0.872|0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant],A|missense_variant|MODERATE|CDKN2A|1787|ENST00000579122|Transcript|2/3||ENST00000579122.1:c.341C>T|ENSP00000464202.1:p.Pro114Leu|Gene3D:1.25.40.20&PROSITE_profiles:PS50297&hmmpanther:PTHR24144&hmmpanther:PTHR24144:SF30&Superfamily_domains:SSF48403|deleterious(0)|probably_damaging(0.997)|rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|protein_coding|32|0.872|0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant],A|synonymous_variant|LOW|CDKN2A|1787|ENST00000579755|Transcript|2/3||ENST00000579755.1:c.384C>T|ENSP00000462950.1:p.Ala128%3D||||rs121913386&CM983988&COSV58683051&COSV58690307&COSV58692178||0|0|0|0|0|0|protein_coding|32||0.98531|0.98118|||||||8.6230001449585|600160_[GENE%3DCDKN2A_PHENOS%3DMelanoma_and_neural_system_tumor_syndrome&155755&Autosomal_dominant/Melanoma&cutaneous_malignant&2&155601&Autosomal_dominant/Melanoma-pancreatic_cancer_syndrome&606719&Autosomal_dominant];CSQ_refseq=A|missense_variant|MODERATE|CDKN2A||NM_000077.4|Transcript|2/3||NM_000077.4:c.341C>T|NP_000068.1:p.Pro114Leu|,A|missense_variant|MODERATE|CDKN2A||NM_001195132.1|Transcript|2/4||NM_001195132.1:c.341C>T|NP_001182061.1:p.Pro114Leu|,A|missense_variant|MODERATE|CDKN2A||NM_001363763.2|Transcript|2/3||NM_001363763.2:c.188C>T|NP_001350692.1:p.Pro63Leu|,A|synonymous_variant|LOW|CDKN2A||NM_058195.3|Transcript|2/3||NM_058195.3:c.384C>T|NP_478102.2:p.Ala128%3D|,A|3_prime_UTR_variant|MODIFIER|CDKN2A||NM_058197.4|Transcript|2/3||NM_058197.4:c.*264C>T||,A|downstream_gene_variant|MODIFIER|CDKN2A-AS1||NR_024274.1|Transcript|||||;CLINVAR_ID=77637;CLINVAR_DETAILS=uncertain_significance(replaced_by_megSAP_based_on_classifications:1x3%2C1x4)%20DISEASE%3DSquamous_cell_carcinoma_of_the_skin%2CCutaneous_melanoma%2CSquamous_cell_lung_carcinoma%2CSquamous_cell_carcinoma_of_the_head_and_neck%2CMalignant_melanoma_of_skin%2CHereditary_cancer-predisposing_syndrome%2CHereditary_cutaneous_melanoma;HGMD_ID=CM983988;HGMD_CLASS=DM;HGMD_MUT=ALT;HGMD_GENE=CDKN2A;HGMD_PHEN="Melanoma";NGSD_COUNTS=0,0;NGSD_SOM_C=10;NGSD_SOM_P=Novartis,Roecken_CheckpointInhibitor,SomaticAndTreatment;NGSD_GENE_INFO=CDKN2A-DT%20(inh%3Dn/a%20oe_syn%3D0.99%20oe_mis%3D0.75%20oe_lof%3Dn/a):CDKN2A%20(inh%3DAD%20oe_syn%3D1.09%20oe_mis%3D1.28%20oe_lof%3D0.20)	AU:BCN50:CU:DP:DP2:DP50:FDP:FDP50:GU:SDP:SUBDP:SUBDP50:TAR:TIR:TOR:TU	0,0:.:1,1:1185:.:.:10:.:1174,1191:0:0:.:.:.:.:0,1	677,685:.:0,0:1269:.:.:3:.:589,593:0:0:.:.:.:.:0,0
